- Biosciences and diagnostics company Enzo Biochem Inc ENZ reported fourth-quarter FY21 revenue growth of 27% year-on-year to $24.8 million. Revenue decreased 24% sequentially.
- The results reflect strong product sales, moderated by a slow-down in COVID-19 testing during the summer months.
- Segments: Enzo Clinical Lab revenue increased 30% Y/Y to $16.8 million. Enzo Life Sciences revenue was $8.1 million, up 38% Y/Y.
- Margin: The consolidated margin remained stable at 40%.
- Non-GAAP EPS was $0.07 versus $(0.07) in the year-ago quarter.
- Selling, general and administrative expenses for the quarter increased 18% to $11.8 million.
- Enzo Biochem held $43.5 million in cash and equivalents.
- Price Action: ENZ shares traded lower by 2.93% at $3.97 in the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
